[Which anticoagulant or antiplatelet treatment for cancer patients with thrombocytopenia ?].

Cancer patients have an increased thrombotic risk of arterial and venous thrombosis. Thrombocytopenia, particularly with anticoagulation, exposes the patient to an increased risk of bleeding but does not reduce the risk of recurrent thrombosis. When platelets are < 50 × 109/l, the strategy regarding anticoagulation must be reassessed.